Gladstone in the News
The Gladstone Institutes is gratified to receive media attention from around the globe. Check out the highlights of recent press coverage of Gladstone scientists and research. For other news, please be sure to follow us on Facebook and Twitter.
Several large clinical trials have demonstrated that a daily oral dose of one or two antiretroviral drugs used to treat HIV infection can prevent infection in an approach known as pre-exposure prophylaxis, or PrEP.
Truvada, the only medication approved by the U.S. Food and Drug Administration for HIV prevention, is effective in blocking the virus even if people do not adhere to their daily regimen perfectly, a new study indicates.
Scientific breakthroughs, one piled on top of another at breakneck speed over the past few years, have put medical researchers on the cusp of curing almost everyone who suffers from hepatitis C, if not wiping out the disease entirely.
Gladstone's Dr. Warner Greene weighs in on latest outbreak of hantavirus at Yosemite National Park.
The Gladstone Institutes is conducting two other trials of Truvada as PrEP. One of those studies is looking at who takes the pill and when it is taken. The study is enrolling 1,600 people on four continents, including San Francisco, Boston and Chicago in the United States.
Les résultats contradictoires des dernières publications montrent combien la lutte contre cette redoutable maladie est difficile.
Testé chez la souris, un médicament contre l’épilepsie du nom de levetiracetam pourrait empêcher les pertes de mémoire. Cette découverte émane du Gladstone Institutes, aux Etats-Unis, et les scientifiques auteurs de l’étude ont fait paraître leurs travaux le 6 août dernier dans la revue PNAS.
Researchers have found that it's possible to improve memory, even reverse memory loss, using a drug typically prescribed to treat epilepsy. Although it's still too early to recommend the drug, levetiracetam, to prevent or treat Alzheimer's disease, research results are promising.
According to a study published online in the Proceedings of the National Academy of Sciences, an FDA-approved anti-epileptic drug has been found to reverse memory loss in a mouse model of Alzheimer's disease .
Une équipe Franco-Américaine a découvert qu’un médicament, le levetiracetam, normalement utilisé pour traiter certains types d’épilepsies améliore les symptômes de la maladie d’Alzheimer chez la souris.